A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease

NCT05104463 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Mild Cognitive Impairment
Dementia

Interventions

DRUG: CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107

Sponsor

CuraSen Therapeutics, Inc.